BDBM575548 (2R,2'R)-2,2'-((((((2,2'-dimethyl-[1,1'- biphenyl]-3,3'-diyl)bis(azanediyl))bis (carbonyl)bis(4-cyclopropylpyridine-6,3- diyl))bis(methylene))bis(azanediyl)bis(3- hydroxypropanoic acid)::US11459339, Example 105

SMILES Cc1c(NC(=O)c2cc(C3CC3)c(CN[C@H](CO)C(O)=O)cn2)cccc1-c1cccc(NC(=O)c2cc(C3CC3)c(CN[C@H](CO)C(O)=O)cn2)c1C

InChI Key InChIKey=DWZMGIOSWBCDMO-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 575548   

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575548(US11459339, Example 105 | (2R,2'R)-2,2'-((((((2,2'...)
Affinity DataIC50: 0.270nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent